MYRIAD GENETICS, INC. Operating Lease, Impairment Loss
MYRIAD GENETICS, INC. (MYGN) reported Operating Lease, Impairment Loss of $13.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseImpairmentLoss · last filed 2024-02-28
- MYRIAD GENETICS, INC. operating lease, impairment loss for the quarter ending 2022-12-31 was $4.40M.
- MYRIAD GENETICS, INC. operating lease, impairment loss for the quarter ending 2022-09-30 was $0.00.
- MYRIAD GENETICS, INC. operating lease, impairment loss for the quarter ending 2022-06-30 was $0.00.
- MYRIAD GENETICS, INC. operating lease, impairment loss for the quarter ending 2022-03-31 was $8.60M.
- MYRIAD GENETICS, INC. operating lease, impairment loss for fiscal 2022 was $13.00M.
| Period end | Operating Lease, Impairment Loss 3 month | Operating Lease, Impairment Loss 6 month | Operating Lease, Impairment Loss 9 month | Operating Lease, Impairment Loss 12 month |
|---|---|---|---|---|
| 2022-12-31 | $4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $4.40M derived: sum of 2 quarters · filed 2024-02-28 | $4.40M derived: sum of 3 quarters · filed 2024-02-28 | $13.00M 10-K · filed 2024-02-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $8.60M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $8.60M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $8.60M 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |